BioAtla BCAB
NASDAQ BCAB
$1.40 +0.08 (+6.06%)
At close: Sep 8, 2026 · 4:00 PM EDT

BioAtla (BCAB) Income towards Parent Company (2020 - 2026)

BioAtla's (BCAB) quarterly Income towards Parent Company came in at $232000.0 in Q2 2026, up 101.26% on a YoY basis from $115273.8 in Q2 2025, and up 102.5% quarter-over-quarter from -$9.3 million in Q1 2026.

Analysis

BioAtla (BCAB) Income towards Parent Company (2020 - 2026) Analysis & Trends

BioAtla (BCAB) has reported Income towards Parent Company for 7 consecutive years, with $232000.0 the latest figure, recorded in Q2 2026.

  • For the quarter ending Q2 2026, Income towards Parent Company rose 101.26% year-over-year to $232000.0; the trailing twelve-month figure through Jun 2026 stood at -$31.9 million (up 48.47% YoY), and the FY2025 full-year result was -$58.5 million, up 17.16% from the prior year.
  • Income towards Parent Company grew to $232000.0 in Q2 2026 per BCAB's latest filing, from -$9.3 million in the prior quarter.
  • Across five years, Income towards Parent Company topped out at $232000.0 in Q2 2026 and bottomed at -$35.7 million in Q2 2023.
  • Historically, Income towards Parent Company has averaged -$20.4 million across 5 years, with a median of -$22.2 million in 2024.
  • The sharpest annual moves came in 2022 and 2026: Income towards Parent Company retreated 29.73% in 2022, then jumped 101.26% in 2026.
  • Over 5 years, Income towards Parent Company stood at -$27.5 million in 2022, then rose by 2.24% to -$26.9 million in 2023, then soared by 41.67% to -$15.7 million in 2024, then surged by 41.48% to -$9.2 million in 2025, then soared by 102.53% to $232000.0 in 2026.
  • According to Business Quant data, Income towards Parent Company over the past three periods registered $232000.0, -$9.3 million, and -$9.2 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Amgen 236.37 Bn 222.38 Bn 7.24 Bn
2 Gilead Sciences 187.38 Bn 184.12 Bn 6.22 Bn
3 Vertex Pharmaceuticals 138.36 Bn 130.51 Bn 2.84 Bn
4 Regeneron Pharmaceuticals 85.09 Bn 77.10 Bn 3.93 Bn
5 Argenx Se 63.93 Bn 58.75 Bn 1.37 Bn
6 Moderna 58.07 Bn 52.94 Bn 52.00 Mn
7 Alnylam Pharmaceuticals 35.59 Bn 32.28 Bn 992.69 Mn
8 Biogen 32.63 Bn 31.34 Bn 1.96 Bn
9 Insmed 27.57 Bn 26.41 Bn 358.27 Mn
10 BioAtla 2.33 Mn 2.33 Mn -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 232,000.00
Mar 31, 2026 -9.29 Mn
Dec 31, 2025 -9.18 Mn
Sep 30, 2025 -13.66 Mn
Jun 30, 2025 -18.41 Mn
Mar 31, 2025 -17.21 Mn
Dec 31, 2024 -15.69 Mn
Sep 30, 2024 -10.59 Mn
Jun 30, 2024 -21.07 Mn
Mar 31, 2024 -23.23 Mn
Dec 31, 2023 -26.90 Mn
Sep 30, 2023 -33.29 Mn
Jun 30, 2023 -35.74 Mn
Mar 31, 2023 -27.45 Mn
Dec 31, 2022 -27.51 Mn
Sep 30, 2022 -25.81 Mn
Jun 30, 2022 -28.91 Mn
Mar 31, 2022 -24.26 Mn
Dec 31, 2021 -23.39 Mn
Sep 30, 2021 -23.62 Mn